USE OF SALIDROSIDE AND DERIVATIVE THEREOF IN PREPARATION OF INHIBITOR MEDICAMENT FOR DISEASES OF OPHTHALMIC FIBROSIS CAUSED BY ABNORMALITIES OF EXTRACELLULAR MATRIX PROTEINS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 26, 2021
app pub date -
Jun 14, 2019
filing date -
Jun 15, 2018
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides use of salidroside and a derivative thereof in preparation of an inhibitor medicament for treating diseases, such as opthmalmic fibrosis, caused by abnormalities of extracellular matrix proteins. The present invention treats and prevents diseases associated with ocular fibrosis such as glaucoma, by inhibiting the expression of extracellular matrix proteins in the eye to prevent fibrosis. The present invention further provides use of an inhibitor medicament for treating and preventing diseases, such as opthmalmic fibrosis, caused by abnormalities of extracellular matrix proteins, the inhibitor medicament comprising an effective amount of salidroside and a derivative thereof as active ingredients.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully